AI is accelerating breakthroughs in pharma and biotech, transforming drug discovery through generative design, biomarker identification, and clinical trial optimization. Its success, however, depends on robust data management—capturing, enriching, and contextualizing data with metadata to ensure quality and usability. Rigid data models often limit scientific progress, while flexible approaches like late binding of schema preserve context and adaptability. Revvity’s Signals Research Suite exemplifies this strategy, providing cloud-native, AI-ready data infrastructure that empowers collaboration, speeds insights, and ensures scalability. With proper governance, AI drives efficiency, innovation, and precision medicine.

Join for free to read